Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery ranked in FT1000: The Financial Times list of Europe’s 1,000 fastest-growing companies

Sygnature Discovery has been ranked 906th in the Financial Times FT1000 .

The FT1000 lists the 1,000 companies in Europe that have achieved the highest percentage growth in revenues between 2012 and 2015.

As the Financial Times describes it, “Innovative and fast-growing companies are the driving force of the European economy in the 21st century. They generate jobs and sustain Europe’s competitiveness.”

Dr Paul J. Clewlow, Senior VP, Business Development, at Sygnature Discovery said, “It is a significant achievement for Sygnature Discovery to be included in the FT1000 and demonstrates the increasing demand that we are seeing for our integrated drug discovery know-how and expertise.  There are only five other pharmaceutical companies in total in this list of Europe’s 1,000 fastest-growing companies and none are competitors of Sygnature Discovery.”

Sygnature Discovery, founded in Nottingham, UK, in 2004, has 180 full-time staff.  80% of the research scientists employed by Sygnature have PhDs.  The company will begin its relocation to Discovery Building at BioCity Nottingham in late April 2017.  Since 2011, nine drug candidates developed by Sygnature Discovery have entered clinical trials.

Latest News

View All

RenaSci’s Sharon Cheetham awarded BPS Fellowship

Sygnature Discovery invests in high-throughput screening capability

Sygnature Discovery moves US base to Kendall…

Sygnature Discovery raises over £2,776 for Cancer…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.